Literature DB >> 31441367

Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification.

Weixin Jin1, Zizhuo Xing1, Yuanli Song1, Chao Huang1, Xuankuo Xu1, Sanchayita Ghose1, Zheng Jian Li1.   

Abstract

Significant amounts of soluble product aggregates were observed during low-pH viral inactivation (VI) scale-up for an IgG4 monoclonal antibody (mAb IgG4-N1), while small-scale experiments in the same condition showed negligible aggregation. Poor mixing and product exposure to low pH were identified as the root cause. To gain a mechanistic understanding of the problem, protein aggregation properties were studied by varying critical parameters including pH, hold time and protein concentration. Comprehensive biophysical characterization of product monomers and aggregates was performed using fluorescence-size-exclusion chromatography, differential scanning fluorimetry, fluorescence spectroscopy, and dynamic light scattering. Results showed IgG4-N1 partially unfolds at about pH 3.3 where the product molecules still exist largely as monomers owing to strong inter-molecular repulsions and favorable colloidal stability. In the subsequent neutralization step, however, the conformationally changed monomers are prone to aggregation due to weaker inter-molecular repulsions following the pH transition from 3.3 to 5.5. Surface charge calculations using homology modeling suggested that intra-molecular repulsions, especially between CH2 domains, may contribute to the IgG4-N1 unfolding at ≤ pH 3.3. Computational fluid dynamics (CFD) modeling was employed to simulate the conditions of pH titration to reduce the risk of aggregate formation. The low-pH zones during acid addition were characterized using CFD modeling and correlated to the condition causing severe product aggregation. The CFD tool integrated with the mAb solution properties was used to optimize the VI operating parameters for successful scale-up demonstration. Our research revealed the governing aggregation mechanism for IgG4-N1 under acidic conditions by linking its molecular properties and various process-related parameters to macroscopic aggregation phenomena. This study also provides useful insights into the cause and mitigation of low-pH-induced IgG4 aggregation in downstream VI operation.

Entities:  

Keywords:  Low pH; antibody aggregation; computational fluid dynamics; viral inactivation

Mesh:

Substances:

Year:  2019        PMID: 31441367      PMCID: PMC6816434          DOI: 10.1080/19420862.2019.1658493

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  51 in total

1.  Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.

Authors:  R Khurana; J R Gillespie; A Talapatra; L J Minert; C Ionescu-Zanetti; I Millett; A L Fink
Journal:  Biochemistry       Date:  2001-03-27       Impact factor: 3.162

Review 2.  Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation.

Authors:  Eva Y Chi; Sampathkumar Krishnan; Theodore W Randolph; John F Carpenter
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

3.  Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc.

Authors:  Ramil F Latypov; Sabine Hogan; Hollis Lau; Himanshu Gadgil; Dingjiang Liu
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

Review 4.  Recovery and purification process development for monoclonal antibody production.

Authors:  Hui F Liu; Junfen Ma; Charles Winter; Robert Bayer
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

5.  Protein stability: electrostatics and compact denatured states.

Authors:  D Stigter; D O Alonso; K A Dill
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

Review 6.  Protein aggregation--pathways and influencing factors.

Authors:  Wei Wang; Sandeep Nema; Dirk Teagarden
Journal:  Int J Pharm       Date:  2010-02-24       Impact factor: 5.875

7.  Kinetics of Monoclonal Antibody Aggregation from Dilute toward Concentrated Conditions.

Authors:  Lucrèce Nicoud; Jakub Jagielski; David Pfister; Stefano Lazzari; Jan Massant; Marco Lattuada; Massimo Morbidelli
Journal:  J Phys Chem B       Date:  2016-03-23       Impact factor: 2.991

8.  Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition.

Authors:  Sampathkumar Krishnan; Eva Y Chi; Jonathan N Webb; Byeong S Chang; Daxian Shan; Merrill Goldenberg; Mark C Manning; Theodore W Randolph; John F Carpenter
Journal:  Biochemistry       Date:  2002-05-21       Impact factor: 3.162

9.  Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates.

Authors:  Rebecca K Brummitt; Douglas P Nesta; Liuquan Chang; Susan F Chase; Thomas M Laue; Christopher J Roberts
Journal:  J Pharm Sci       Date:  2011-01-06       Impact factor: 3.534

10.  Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold.

Authors:  Alice R Mazzer; Xavier Perraud; Jennifer Halley; John O'Hara; Daniel G Bracewell
Journal:  J Chromatogr A       Date:  2015-09-02       Impact factor: 4.759

View more
  5 in total

Review 1.  Recombinant antibodies aggregation and overcoming strategies in CHO cells.

Authors:  Tingting Xu; Jihong Zhang; Tianyun Wang; Xiaoyin Wang
Journal:  Appl Microbiol Biotechnol       Date:  2022-05-24       Impact factor: 4.813

2.  Sensitive, homogeneous, and label-free protein-probe assay for antibody aggregation and thermal stability studies.

Authors:  Salla Valtonen; Emmiliisa Vuorinen; Ville Eskonen; Morteza Malakoutikhah; Kari Kopra; Harri Härmä
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

3.  Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.

Authors:  Michael D Swanson; Shantel Rios; Sarita Mittal; George Soder; Vibha Jawa
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

4.  Application study of infrared free-electron lasers towards the development of amyloidosis therapy.

Authors:  Mikiko Jindo; Kazuhiro Nakamura; Hisashi Okumura; Koichi Tsukiyama; Takayasu Kawasaki
Journal:  J Synchrotron Radiat       Date:  2022-08-12       Impact factor: 2.557

5.  Ionic Liquid-Based Strategy for Predicting Protein Aggregation Propensity and Thermodynamic Stability.

Authors:  Talia A Shmool; Laura K Martin; Richard P Matthews; Jason P Hallett
Journal:  JACS Au       Date:  2022-09-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.